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A B S T R A C T
Background
This article describes the second update of a Cochrane review on the effectiveness of laxatives for the management of constipation in
people receiving palliative care. Previous versions were published in 2006 and 2010 where we also evaluated trials of methylnaltrexone;
these trials have been removed as they are included in another review in press. In these earlier versions, we drew no conclusions on
individual effectiveness of different laxatives because of the limited number of evaluations. This is despite constipation being common
in palliative care, generating considerable suffering due to the unpleasant physical symptoms and the availability of a wide range of
laxatives with known differences in effect in other populations.
Objectives
To determine the effectiveness and differential efficacy of laxatives used to manage constipation in people receiving palliative care.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL;The Cochrane Library),MEDLINE, EMBASE, CINAHL
and Web of Science (SCI & CPCI-S) for trials to September 2014.
Selection criteria
Randomised controlled trials (RCTs) evaluating laxatives for constipation in people receiving palliative care.
Data collection and analysis
Two authors assessed trial quality and extracted data. The appropriateness of combining data from the studies depended upon clinical
and outcome measure homogeneity.
Main results
We identified five studies involving the laxatives lactulose, senna, co-danthramer, misrakasneham, docusate and magnesium hydroxide
with liquid paraffin. Overall, the study findings were at an unclear risk of bias. As all five studies compared different laxatives or
combinations of laxatives, it was not possible to perform a meta-analysis. There was no evidence on whether individual laxatives were
more effective than others or caused fewer adverse effects.
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Authors’ conclusions
This second update found that laxatives were of similar effectiveness but the evidence remains limited due to insufficient data from a
few small RCTs. None of the studies evaluated polyethylene glycol or any intervention given rectally. There is a need for more trials to
evaluate the effectiveness of laxatives in palliative care populations. Extrapolating findings on the effectiveness of laxatives evaluated in
other populations should proceed with caution. This is because of the differences inherent in people receiving palliative care that may
impact, in a likely negative way, on the effect of a laxative.
P L A I N L A N G U A G E S U M M A R Y
Laxatives for the management of constipation in people receiving palliative care
Background
People with an incurable illness may receive palliative care, which involves making the person as comfortable as possible by controlling
pain and other distressing symptoms. People receiving palliative care commonly experience constipation. This is as a result of the use of
medicines (e.g. morphine) for pain control, as well as disease, dietary and mobility factors. There is a wide range of laxatives available.
The aim of this review was to determine what we know about the effectiveness of laxatives for the management of constipation in
people receiving palliative care.
Study characteristics
We searched medical databases for clinical trials of the use of laxatives for constipation in people receiving palliative care. Two review
authors assessed study quality and extracted data.
Key results and quality of evidence
We identified five studies involving 370 people. The laxatives evaluated were lactulose, senna, co-danthramer combined with poloxamer,
docusate and magnesium hydroxide combined with liquid paraffin. Misrakasneham was also evaluated; this is a traditional Indian
medicine and is used as a laxative, containing castor oil, ghee, milk and 21 types of herbs.
There was no evidence on which laxative provided the best treatment. However, the review was limited as the evidence was from only
five small trials and patient preference and cost were under evaluated. Further rigorous, independent trials are needed to evaluate the
effectiveness of laxatives.
B A C K G R O U N D
Description of the condition
This is the second update of a Cochrane review first published
in 2006 (Miles 2006), and subsequently in 2010 where trials of
methylnaltrexone were also evaluated; these trials have been re-
moved as they are included in another review in press (Candy
2011).
There are many definitions of constipation (Gray 2011). In part,
this reflects differences in what is normal; for instance in healthy
people the range of bowel evacuations can be from three times a
day to three times a week (Thompson 1999). However, in gen-
eral, definitions of constipation, including the Rome III Criteria
(Longstreth 2006), make reference to:
• infrequent, difficult or incomplete bowel evacuation that
may lead to pain and discomfort;
• stools that can range from small, hard ’rocks’, to a large
bulky mass;
• a sensation of incomplete evacuation.
Constipation can generate considerable suffering, including ab-
dominal pain and distension, anorexia, nausea, general malaise
and in faecal impaction, an overflow of diarrhoea. It can also cause
headaches, halitosis, restlessness and confusion. There are signifi-
cant psychological and social consequences that can contribute to
a reduction in a person’s quality of life. The suffering can be so se-
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vere that some people with opioid-induced constipation choose to
decrease or even discontinue opioids, thereby preferring to expe-
rience inadequate pain control rather than the symptoms of con-
stipation (Thomas 2008).
The causes of constipation can be classified as follows.
• Lifestyle-related, such as having a low-fibre diet, and a poor
fluid intake. Physical inactivity can bring about a reduction in
abdominal muscle activity and stimulation producing a ’sluggish
bowel’ (Winney 1998). In people who are being treated in a
healthcare setting, a lack of privacy or environmental factors, or
both, such as having to use a bedpan or a commode in a
communal area can inhibit bowel function and predispose to
constipation in people who are already debilitated.
• Disease-related for mechanical-anatomical reasons, such as
an anal fissure, colitis, diverticular disease, haemorrhoids, hernia
and rectocoele. In the common cancers, particularly bowel and
ovarian cancer, gastrointestinal symptoms are a frequent
complication (Droney 2008; Dunlop 1989). There are also
metabolic and physiological consequences of various conditions
that increase the tendency for constipation, including
paraneoplastic hypercalcaemia, hypokalaemia, obstructed venous
outflow with right heart failure and intestinal lymphoedema.
• Drug-induced, there is a wide range of drugs that have
constipation as an adverse effect. These drugs include neurotoxic
chemotherapy agents, antiemetics, anticholinergics and diuretics.
Good palliative care is predicated on a need to achieve optimal
pain control; many of the drugs used to achieve this, such as
opioids, cause constipation.
Constipation is a common problem in palliative care, where the
overall estimated incidence ranges, depending on the definition
of constipation used, from 18% to 90% of people (Clark 2012;
Laugsand 2009; Sykes 1998). The causes in this population are
often multifactorial relating to poor dietary intake, physical inac-
tivity, disease and treatment related. For people receiving palliative
care receiving opioid treatments, the estimates of the incidence of
constipation are even higher: from 72% (Droney 2008) to 87%
of people (Sykes 1998).
Description of the intervention
Prevention and management of constipation relates to cause. Peo-
ple receiving palliative care are at risk of developing constipation
as a result of changes in their lifestyle. These are attributable to dis-
ease progression and are unlikely to be readily resolved. However,
given that constipation for the majority of people receiving pal-
liative care has the potential to be drug-induced, management to
promote satisfactory bowel movements commonly involves some
form of pharmaceutical administration, of which the first line of
recommended treatment is commonly a laxative (Caraceni 2012;
NICE 2012; Scottish Palliative Care Guidelines 2014).
There is a wide range of laxatives that work by softening faecal
matter or through direct stimulation of peristalsis, or both. Lax-
atives are generally classified according to their mode of action:
bulk-forming laxatives, osmotic laxatives, stimulant laxatives, and
faecal softeners and lubricants. Widely used laxatives are the stim-
ulant preparations: these include senna, bisacodyl, sodium pico-
sulfate and wheat bran. In a survey in Spain, the most commonly
prescribed was lactulose (Noguera 2010). The authors suggest this
is because of ease of dosing, its sweet taste and that it is often
freely available through prescription, thereby requiring less finan-
cial burden to the person.
How the intervention might work
Laxatives work in various ways. Bulk-forming laxatives involve the
absorption of large amounts of fluids. This incurs a stretch reflex
on the intestinal wall, which results in reflexive, propulsive activity,
leading to bowel movement. These types of laxatives are not ordi-
narily recommended in palliative care, as peoplemay not maintain
a necessary adequate fluid intake to avoid intestinal obstruction
or faecal impaction. Osmotic laxatives increase water content and
thereby the softness and volume of the stool. Besides lactulose,
osmotic laxatives include polyethylene glycol, sorbitol and mag-
nesium citrate. Stimulant laxatives induce propulsive motility. In-
dividually, within these mode of action groups, laxatives work in
different ways.
• Bisacodyl works after bacterial hydrolysis in the intestines.
• Sodium picosulfate and senna only after hydrolysis in the
large intestine (colon).
• Lactulose is fermented in the intestine producing carbon
dioxide and hydrogen, which results in acidification of the stool.
Due to irritation of the colon wall this promotes peristalsis
(Droney 2008).
Why it is important to do this review
Laxatives are an accepted treatment in constipation. Reviewing
the evidence base to support their use is necessary to compare and
assess individual laxatives in terms of effect and harm, as well as a
person’s preference and cost. There are published clinical practice
recommendations in palliative care that have been informed by
earlier versions of this review including those from the European
Palliative Care Association (Caraceni 2012). It is timely to update
this review as the last search was undertaken in 2010.
It is important to highlight that there are other reviews on laxatives
in other populations that have identified multiple trials, of note is
one Cochrane review on lactulose in comparison with polyethy-
lene glycol for chronic constipation (Lee-Robichaud 2010). This
review concluded on the basis of evidence from 10 trials that
polyethylene glycol should be used in preference to lactulose. In
extrapolating them to a palliative care population, these results
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must be treated with care as they came from studies whose pop-
ulations are different. Moreover, it is important to evaluate the
effectiveness of laxatives in palliative care populations, because of
the differences inherent in this group that may impact, in a likely
negative way, on the effect of a laxative. In particular, the multi-
factorial pathophysiology of constipation in people with advanced
disease. This includes but is not limited to the impact of disease
progression, that certain terminal illnesses have a rapid course,
that people may have from co-morbidities, have multiple organ
failure, have increasing frailty, reduced liquid and food intake, and
may be receiving various treatments including multiple different
drugs (Bader 2012; Sanderson 2014). People receiving palliative
care may also have a higher risk than other populations of experi-
encing adverse effects from the laxatives used.
Sincethe mid-2000s, mu-opioid antagonists, such as methylnal-
trexone have been developed and have been recommended as an al-
ternative to laxatives. These drugs are generally only recommended
when traditional laxatives have failed (Caraceni 2012; Scottish
Palliative Care Guidelines 2014). A separate Cochrane review on
mu-opioids antagonists in people receiving palliative care is in
press.
O B J E C T I V E S
To determine the effectiveness and differential efficacy of laxatives
used to manage constipation in people receiving palliative care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of the efficacy of laxatives
were included.
We applied no language restrictions and allowed both published
and unpublished studies.
Types of participants
• Eligible studies concerned adults receiving palliative care
who were given a laxative, either as a prophylactic or because
they were constipated. These studies could be undertaken in any
care setting (inpatient, outpatient, day-care, community).
• We also included studies of people whose disease was
described as advanced or end-stage irrespective of care setting.
• We excluded studies that included healthy volunteers,
participants with constipation as a result of drug misuse and
participants with constipation arising from bowel obstruction.
Types of interventions
All laxatives were eligible for inclusion. This was irrespective of
routes of administration (oral, rectal or another route) and for
doses that were evaluated in the management of constipation in
palliative care for cancer and other life-limiting progressive dis-
eases. Laxatives included, for example, senna and lactulose. The
comparator could be placebo, usual care or another active inter-
vention such as a study of comparison between two laxatives.
Types of outcome measures
Studies were eligible if the outcome measures were reported in
terms of relief of constipation. These could include:
• laxation response, such as change in frequency of defecation
and ease of defecation;
• relief of systemic and abdominal symptoms related to
constipation, such as an reduced appetite, abdominal pain and
distension, and confusion;
• change in quality of life;
• need for additional laxatives, as in the use of ’rescue’
laxatives, such as a rectal suppository or an enema; and
• acceptability and tolerability including participant
preference.
We collected information on adverse effects, including:
• nausea/vomiting;
• pain;
• flatus;
• diarrhoea; and
• faecal incontinence.
Primary outcomes
• Laxation response. Laxation response could be measured by
reporting the time to a bowel movement or frequency of having
a bowel movement. It could be by the need for an additional
laxative beyond those that were evaluated in the trial or measured
by whether the person had difficulty or completeness of
defecation. The type of stool passed, such as in volume and
consistency, could also be measured by the Bristol Stool Chart
(Lewis 1997).
• Adverse events.
Secondary outcomes
• Participant preference.
• Relief of other constipation-associated symptoms, such as
abdominal pain, nausea, vomiting and loss of appetite.
Search methods for identification of studies
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The aim of the search strategy was to be as comprehensive as pos-
sible. We updated our 2014 review search strategy as in earlier ver-
sions using three approaches: a literature search for recent reviews,
expert consultation and a search of the British National Formu-
lary.
Electronic searches
Weused both English andAmerican spellings and names. Searches
were restricted to human participants. The subject search used a
combination of controlled vocabulary and free-text terms based on
a strategy for searching MEDLINE. Appendix 1 details the search
strategies used for this current update. We did not seek studies
pre-dating 1966.
For this update, we searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library), Issue 8 of 12, 2014.
• MEDLINE (OVID) August 2010 to 9 September 2014.
• EMBASE (OVID) August 2010 to 9 September 2014.
• CINAHL (EBSCO) August 2010 to September 2014.
• Web of Science (SCI & CPCI-S) 2010 to September 2014.
Previously, for the original review and the first updated version,
the following was searched up to 2010 unless otherwise stated:
• CENTRAL (The Cochrane Library Issue 8, 2010).
• MEDLINE search from 1966 to January 2005 - (update to
August 2010).
• EMBASE search from 1980 to January 2005 - (update to
August 2010).
• CANCERLIT from 1980 to March 2001.
• Science Citation Index from 1981 to March 2005.
• Web of Science March 2005 to August 2010.
• CINAHL from 1982 to March 2005 (update to August
2010).
• Databases that provide information on grey literature:
SIGLE from 1980 to 2005 (containing British Reports,
Translations and Theses), NTIS, DHSS-DATA and Dissertation
Abstracts from 1961 to 2005, and Index to Thesis to October
2010.
• Conference proceedings from both international and
national conferences were handsearched and databases on
conference proceedings were accessed - Boston Spa Conferences
(containing Index of Conference Proceedings) and Inside
Conferences 1996 to 2001, Index to Scientific and Technical
Proceedings from 1982 to 2005. In addition, conference
proceedings for the European Association of Palliative Care 2007
to 2010 were handsearched.
• National Health Service National Research Register
(containing Medical Research Council Directory) (inception to
2007).
Searching other resources
Reference searching
We searched the MetaReg-
ister of controlled trials (www.controlled-trials.com/mrct), clin-
icaltrials.gov (www.clinicaltrials.gov), the World Health Organi-
zation (WHO) International Clinical Trials Registry Platform (
apps.who.int/trialsearch/) to October 2014. We also searched ref-
erence lists and undertook a forward citation check of all included
studies. We also searched reference lists from relevant review ar-
ticles and sought contact with representatives of pharmaceutical
companies for further trial evaluations.
Data collection and analysis
Selection of studies
Two review authors (BC/LJ or BC/PL) independently screened
citations identified in our searches for eligibility. If it was not pos-
sible to accept or reject a study with certainty, we obtained the
full text of the study for further evaluation. Two review authors
independently assessed studies in accordance with the above in-
clusion criteria. We resolved any differences in opinion by discus-
sion. We included a PRISMA study flow diagram (Moher 2009),
to document the screening process, as recommended in Part 2,
Section 11.2.1, of the Cochrane Handbook on Systematic Reviews
of Interventions (Higgins 2011).
Data extraction and management
We designed a data extraction form specifically for the review. If
possible, we obtained the following information for each of the
eligible studies:
• study methods (trial design, duration, allocation method,
blinding, setting, study inclusion criteria);
• participants (number, age, sex, drop-outs/withdrawals);
• laxative(s) (type, dose(s), route of delivery, control used);
• outcome data including laxation response;
• tolerance and adverse effects.
Assessment of risk of bias in included studies
Two review authors assessed the quality of included RCTs accord-
ing to the criteria described in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). Where differences of
opinion existed, we resolved them by consensus with the other
review authors. We assessed five main sources of systematic bias
for each included study.
• Randomisation allocation sequence generation.
• Concealment of allocation sequence.
• Blinding of participants, personnel and outcome assessors.
• Level of completeness of outcome data.
• Selective outcome reporting.
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We assessed each domain by whether the criteria for that domain
had been met (i.e. low risk of bias), whether they had not (i.e.
high risk of bias) or whether it was judged ’unclear’ because of
insufficient reporting.
Based on these criteria, we categorised a trial as:
• low risk of bias if all quality criteria met;
• unclear risk of bias if one or more of the criteria was judged
as unclear;
• high risk of bias if one or more criteria not met.
Measures of treatment effect
We report study results organised by type of intervention treat-
ments evaluated.
Wemeasured treatment effects using dichotomous data, an ordinal
rating scale or qualitative evidence.
Dichotomous data
Where dichotomous data were reported, we generated odds ratios
(ORs) and their 95%confidence intervals (CIs).We also calculated
the risk difference (RD), which is the absolute difference in the
proportions in each treatment group.
Continuous data
We assessed effects measures for ordinal data as continuous data.
We generated the mean difference (MD) for continuous and or-
dinal data where the data were provided as a mean and standard
deviation (SD).
If baseline data were reported pre-intervention and post-interven-
tion, we reported means or proportions for both intervention and
control groups and calculated the change from baseline. For cross-
over trials, we only generated, as appropriate, an OR or MD for
pre-cross-over results.
If limitations in the study data prevented reporting an OR, RD or,
if continuous data, an MD, we reported the results with caution
due to lack of transparency of the evidence.
Qualitative evidence
We planned if there had been any qualitative data reported in the
included studies to extract it in consultation with the Cochrane
Qualitative Methods Group. Such qualitative data may aim to
capture the participant’s views on the value of the intervention.
Unit of analysis issues
Weplanned to seek statistical advice if we had identified trials using
a cluster design (in which participants were randomly assigned at
group level).
Dealing with missing data
Given the nature of this field, there was a significant amount of
missing data as a result of trial attrition due to the death of the
participant.
Where data were not reported we attempted to contact study au-
thors. For studies using continuous outcomes in which SDs were
not reported, and no information was available from the authors,
we calculated the SDs using the standard error of themean (SEM).
Assessment of heterogeneity
If meta-analysis had been possible, we would have assessed statis-
tical heterogeneity between the studies using the Chi2 test and the
I2 statistic (we considered a Chi2 P value of less than 0.05 or an I2
value of 50% or more than to indicate substantial heterogeneity).
Assessment of reporting biases
We planned to explore publication bias using funnel plots.
Data synthesis
Where study data were of sufficient quality and sufficiently similar
(in diagnostic criteria, intervention, outcome measure, length of
follow-up and type of analysis), we planned to combine data in
a meta-analysis to provide a pooled effect estimate. We would
have used a fixed-effect model in the first instance. If there was
no statistical heterogeneity, we would have used a random-effects
model to check the robustness of the fixed-effect model.
Subgroup analysis and investigation of heterogeneity
If heterogeneity had been identified in ameta-analysis, we planned
to undertake subgroup analysis to investigate its possible sources.
To explore clinical heterogeneity and investigate the effect modi-
fication of specific participant characteristics that have been iden-
tified in general palliative care populations as effect modifiers, we
planned to exclude studies of a higher risk of bias from subgroup
analysis.
Sensitivity analysis
If sufficient studies were available, we planned to perform, in a
meta-analysis, sensitivity analyses in order to explore the influence
of:
• publication status by excluding unpublished studies;
• study quality by excluding studies that had a high risk of
bias;
• validated measures of outcome effect by excluding studies
that did not use validated measures.
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’Summary of findings’ tables
We had planned to use the GRADE system to assess the quality
of the evidence associated with specific outcomes (e.g. pain reduc-
tion, quality of life improvement, adverse effects) (Schünemann
2008), and construct a ’Summary of findings’ table using the
GRADE software. Although the review authors note that it is pos-
sible to create a ’Summary of findings’ table despite the lack of
meta-analysis, because the search found of the small cohort of het-
erogeneous trials comprising of different laxatives and outcomes,
we did not construct a ’Summary of findings’ table as it would not
add any meaning for the reader.
R E S U L T S
Description of studies
Results of the search
From the searches undertaken for the earlier versions of this review
we identified three published trials (Agra 1998; Ramesh 1998;
Sykes 1991a). We also identified a fourth relevant, but unpub-
lished, study (Sykes 1991b).We excluded 20 studies that had war-
ranted further consideration. They were mostly excluded as they
were evaluating the effect of laxatives in a non-palliative care pop-
ulation.
The 2014 update search identified 717 unique citations (ofMED-
LINE, EMBASE, CENTRAL, CINAHL and Web of Science
databases) of which one trial was included (Tarumi 2013). We ex-
cluded a further study that had warranted further consideration at
full text as it was evaluating laxatives in a non-palliative care popu-
lation. We also identified two ongoing trials that may fit inclusion
criteria when completed (NCT01189409 2014; NCT01416909
2014). In total, we reviewed five RCTs in this update. Figure 1
charts the project progress from screening to inclusion.
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Figure 1. Study flow diagram for update search in 2014.
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Included studies
The five RCTs analysed 370 participants (Agra 1998; Ramesh
1998; Sykes 1991a; Sykes 1991b; Tarumi 2013). Two studies were
of cross-over design (Sykes 1991a; Sykes 1991b); the others were
parallel design. The studies were undertaken in Canadian, British,
Spanish and Indian populations. All participants were at an ad-
vanced stage of disease and were cared for within a palliative care
setting. All participants had a cancer diagnosis, apart from four
participants (5% of sample) in one study (Tarumi 2013). The
mean age of participants ranged from 61 to 75 years. The laxa-
tives evaluated were all taken orally, they were senna (Agra 1998;
Ramesh 1998; Sykes 1991a; Tarumi 2013); lactulose (Agra 1998;
Sykes 1991a); co-danthramer plus poloxamer (Sykes 1991a);mag-
nesiumhydroxide plus liquid paraffin (Sykes 1991b), anddocusate
(Tarumi 2013). One study also evaluated the effect of misrakasne-
ham (Ramesh 1998), a drug used in traditional Indian medicine
as a purgative, containing castor oil, ghee, milk and 21 types of
herbs. We identified no studies of interventions given rectally.
Study comparisons weremostly between different laxatives, others
involved an active control of a placebo plus a common laxative.
Two studies used in one or both arms a combination of laxatives;
senna plus lactulose (Sykes 1991a; Sykes 1991b), and magnesium
hydroxide plus liquid paraffin (Sykes 1991b). Another study used
an active control of placebo and senna (Tarumi 2013). All stud-
ies measured laxation response and adverse effects. Commonly,
laxation response was captured by self report and was assessed at
several time points over one or two weeks. Timing of follow-up
was not clear in two studies (Ramesh 1998; Sykes 1991a). None
of the studies reported significant baseline differences between the
trial arms.
Excluded studies
We excluded 21 studies after assessing full-text publications, rea-
sons for exclusion included not a trial, outcomes not on laxation
or intervention was not a laxative. See table on Characteristics of
excluded studies table.
Risk of bias in included studies
All trials under-reported key design features. Much of the infor-
mation from the studies was of an unclear risk of bias. See Figure
2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Two studies described how they generated random allocation (
Ramesh 1998; Tarumi 2013), and three studies did not describe
how they generated the random allocation to trial arms (Agra
1998; Sykes 1991a; Sykes 1991b).Only one of the studies reported
the methods used to conceal random allocation (Tarumi 2013).
Blinding
Owing to differences in the physical characteristics of the interven-
tion laxative and comparison, blinding was not possible in four of
the trials, (Agra 1998; Ramesh 1998; Sykes 1991a; Sykes 1991b).
Complete details on who was blinded were provided by one study
(Tarumi 2013).
Incomplete outcome data
Attrition rates were provided by all studies. Three studies were
are a low risk of attrition bias; over three-quarters of participants
completed the studies and the numbers and reasons for dropping
out were similar in trial arms (Agra 1998; Ramesh 1998; Tarumi
2013). The other studies were at a higher risk of attrition bias
as higher proportions of participants dropped out, 49% in one
(Sykes 1991a) and 64% in the other (Sykes 1991b). In these two
studies, no participants dropped because of inefficacy and one
participant in one trial dropped out because of stomach cramps
associated with taking the intervention laxatives of lactulose with
senna (Sykes 1991b).
Selective reporting
It is unclear if any of the studies were at risk of reporting bias as
there was insufficient information to permit judgement of ’low
risk’ or ’High risk’.
Other potential sources of bias
The two cross-over studies did not involve, between the different
interventions, a washout period when the participants did not
receive any active trial treatment (Sykes 1991a; Sykes 1991b).
Washout is intended to prevent continuation of the effects of the
trial treatment from one period to another.
Effects of interventions
Co-danthramer plus poloxamer versus senna plus
lactulose
One cross-over study of 51 participants evaluated the effective-
ness of co-danthramer plus poloxamer versus senna plus lactulose
(Sykes 1991a). Both laxatives were in a liquid format. Neither
dosage nor details of the data analyses were reported in full. The
study analysed laxation response according to opioid use. Table 1
details findings reported.
Laxation response
The trialists report that the 17 participants receiving 80 mg or
more of a strong opioid analgesia (either diamorphine or mor-
phine) “had a significantly higher stool frequency when taking lac-
tulose plus senna than while receiving co-danthramer, P < 0.01”.
The study reported no statistical difference for the other partic-
ipants receiving either a lower dose of opioid or no opioid. For
participants’ assessments of bowel function, they reported no sta-
tistical difference between laxatives.
Need for additional laxatives
Nineteen participants required rescue laxatives in the co-dan-
thramer plus poloxamer group and nine in the senna plus lactulose
group.
Constipation-associated symptoms
The study did not evaluate constipation-associated symptoms.
Acceptability and tolerability
Diarrhoea resulted in suspension of laxative therapy for 24 hours
for 15 participants while taking senna plus lactulose and for five
participants while taking co-danthramer plus poloxamer. The tri-
alists reported that six instances of diarrhoea occurred at opioid
doses of at least 80 mg/day while taking senna plus lactulose and
none occurred while taking co-danthramer plus poloxamer. Two
participants reported perianal soreness and burning while taking
co-danthramer plus poloxamer. Participant preference was similar
between the trial arms (15 for senna plus lactulose and 14 for co-
danthramer plus poloxamer), although they reported more partic-
ipants disliked the flavour of co-danthramer plus poloxamer com-
pared with senna plus lactulose.
Magnesium hydroxide plus liquid paraffin versus
senna plus lactulose
One unpublished cross-over trial involved 118 participants (Sykes
1991b). It evaluated the effectiveness of
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• one week of magnesium hydroxide plus liquid paraffin
(mean dose per cross-over group 45 mL if taken in first week and
49 mL daily if taken in second week), versus
• one week of senna plus lactulose (mean dose per cross-over
group of 34 mL if taken in the first week and 38 mL daily if
taken in the second week).
Forty-two of the 118 participants completed the trial. Results were
not analysed in terms of whether different opioid doses influenced
laxative results. Table 2 details findings.
Laxation response
No difference was reported in laxation response between the cross-
over groups. The findings did not change by dose of opioid or
by the order given in the cross-over of senna plus lactulose with
magnesium hydroxide plus liquid paraffin. They reported that the
dosage of magnesium hydroxide plus liquid paraffin required to
achieve the same frequency of bowel movements was significantly
higher than the dosage required with senna plus lactulose. Using
data from the pre-cross-over week, there was no significant differ-
ence in participants’ perception of being constipated, or normality
of bowel function. At the end of the trial, 54% of participants
considered their bowel movements were normal.
Need for additional laxatives
Participants in both groups required rescue laxatives. They re-
ported that a significantly greater proportion of participants
needed rescue laxatives while taking senna plus lactulose compared
with magnesium hydroxide plus liquid paraffin.
Constipation-associated symptoms
The study did not evaluate constipation-associated symptoms.
Acceptability and tolerability
There was no significant difference between treatments in partici-
pants reporting diarrhoea. In both groups, one participant found
the treatment intolerably nauseating. One participant, while tak-
ing senna plus lactulose, experienced gripping abdominal pain.
More participants preferred senna plus lactulose rather than mag-
nesium hydroxide plus liquid paraffin.
Misrakasneham versus senna
One small study of 36 participants evaluated the effectiveness of
up to 10 mL of misrakasneham versus senna 24 to 72 mg (both
in liquid format) over two weeks (Ramesh 1998). Participants in
the trial were taking various doses of morphine but results were
not analysed in terms of whether different opioid dose influenced
laxative results. Table 3 details the findings.
Laxation response
There was no statistical difference between the misrakasneham
and the senna groups in satisfactory bowel movements (defined as
the comfortable feeling that a person experienced after having a
free, effortless bowel movement at a frequency acceptable to him
or her).
Need for additional laxatives
Six participants required rescue laxatives, five of whom were in the
senna group.
Constipation-associated symptoms
The study did not evaluate constipation-associated symptoms.
Acceptability and tolerability
Nausea, vomiting and colicky pain were reported by two partici-
pants taking misrakasneham. None of the participants withdrew
because of inefficiency. Participant preference was split between
the groups.
Senna versus lactulose
One study of 75 participants evaluated the effectiveness of lactu-
lose 10 mg to 40 mg versus senna 12 mg to 48 mg (both laxa-
tives were in liquid format) over four weeks (Agra 1998). Doses
of the laxatives were increased according to clinical response; the
study authors do not provide details on mean doses. Results were
not analysed in terms of whether different opioid doses influenced
laxative results. Table 4 details the findings.
Laxation response
There was no statistical difference between the senna and the lac-
tulose groups in laxation response, in defecation-free periods and
in the mean number of defecation days (senna: mean 8.9 days, SD
6.6; lactulose: mean 10.6 days, SD 7.3).
Need for additional laxatives
Thirty-seven per cent of participants completing the study re-
quired combined lactulose and senna to relieve constipation.
Constipation-associated symptoms
There was no statistical difference in the general state of health of
the participants between the trial arms.
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Acceptability and tolerability
An equal number of participants, three per trial group, reported
diarrhoea, vomiting and cramps. There was no significant differ-
ence in the number of participants who dropped out between the
trial arms. Participant preference was not evaluated.
Docusate plus senna versus placebo plus senna
One study of 74 participants evaluated docusate plus senna (sen-
nosides) versus an active control of placebo plus senna over 10 days
(Tarumi 2013). Details of the data analyses were not reported in
full. Results were not analysed in terms of whether different opioid
doses influenced laxative results. Table 5 details the findings.
Laxation response
The study reported no statistical difference in laxation between do-
cusate plus senna and placebo plus senna. This was in volume, dif-
ficulty and completeness of defecation, and having a bowel move-
ment on 50% of the study days (where for instance the OR was
0.52 (95% CI 0.17 to 1.57)). Using the Bristol Stool chart, there
was a significant difference (P value = 0.001) in stool consistency
between the trial arms; with more participants in the placebo plus
senna group having Type 4 (smooth and soft) or Type 5 (soft
blobs) stools, and more participants in the docusate plus senna
group having Type 3 (sausage like) or Type 6 (mushy) stools.
Need for additional laxatives
At least one type of additional laxative was given to 74% of partic-
ipants in the placebo plus senna group and 68.6% of participants
in the docusate plus senna group. The difference was not signifi-
cant (P value = 0.77).
Constipation-associated symptoms
The study measured symptoms, such as shortness of breath and
drowsiness, using the Edmonton Symptom Assessment System.
They report no significant difference between the trial arms.
Acceptability and tolerability
Twenty-five participants in the docusate plus senna group and
eight in the placebo plus senna group dropped out; reasons for
attrition were not related to the treatments. Adverse effects were
not reported. Preference was not measured.
D I S C U S S I O N
Summary of main results
This review is the second update of a Cochrane review on the effec-
tiveness of laxatives for the management of constipation in people
receiving palliative care. Previous versions were published in 2006
and 2010 where we also evaluated trials of methylnaltrexone; we
have removed these trials as they are included in another review in
press. This current review sought to determine the effectiveness of
the administration of laxatives for the management of constipa-
tion in people receiving palliative care. We included five studies,
four of which were identified in the earlier review. Studies either
compared the effectiveness of two different laxatives, or compared
the laxative with an active control.
No differences in effectiveness were demonstrated in:
• lactulose compared with senna;
• senna plus lactulose compared with magnesium hydroxide
plus liquid paraffin;
• misrakasneham compared with senna;
• docusate plus senna compared with placebo plus senna.
In one study, there were mixed findings on senna plus lactu-
lose compared with co-danthramer plus poloxamer (Sykes 1991a).
There was a significant difference (P value <0.01) in the subgroup
of 17 participants receiving strong opioid analgesia that favoured
senna plus lactulose compared with co-danthramer plus polox-
amer in stool frequency and overall participants took fewer rescue
medications (9/51 in senna plus lactulose group compared with
19/51 in co-danthramer plus poloxamer group). However, there
was no difference between the laxatives in participants’ overall as-
sessment of their bowel function.
Four studies report that a few (one to three) participants experi-
enced adverse effects. Themost common adverse effects were nau-
sea, vomiting, diarrhoea and abdominal pain. In the study com-
paring senna plus lactulose with magnesium hydroxide plus liquid
paraffin, one participant from each group withdrew because of
intolerable nausea and gripping abdominal pain.
Participant preferences were reported in two studies; one study
showed a preference for senna plus lactulose over magnesium hy-
droxide plus liquid paraffin (Sykes 1991b). The other study found
no difference in preference between misrakasneham and senna
(Ramesh 1998).
In all included studies, a number of participants remained consti-
pated and were given rescue laxatives. None of the studies explored
differences between responders and non-responders in follow-up
characteristics, such as disease progression or drug use (in partic-
ular opioids).
Overall completeness and applicability of
evidence
Our review findings are limited. The studies were few, and were
overall of unclear risk of biased findings. The studies involved
small sample sizes and the two cross-over trials did not involve a
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washout period between testing the effect of the different treat-
ments. There was limited overlap in which laxative was evaluated,
this prevented their results being combined in an analysis. Partici-
pant preference was under-explored. Only one new trial was com-
pleted since the last search in 2010. However, there is perhaps little
incentive for pharmaceutical companies to sponsor evaluations in
established treatments such as laxatives and in the relatively small
group of people in palliative medicine (Bader 2012). Laxatives
are extensively used in this patient group but there remains little
known about the differences in effect and adverse events between
the laxatives available. It is unknown whether some laxatives may
be more suitable for certain people receiving palliative care than
other people.
Quality of the evidence
There were issues in the quality of the evidence. Sample sizes of
most studies (four of five) were likely to be under-powered to
find a true effect as they involved fewer than 100 participants.
Studies also had somemethodological limitations; in three studies,
double-blinding was not possible because the drugs differed in
presentation (Ramesh 1998; Sykes 1991a; Sykes 1991b); in two
studies, there was a high attrition rate of over 50% (Sykes 1991a;
Sykes 1991b).However, given this was a palliative care population,
attrition of this magnitude is not unusual.
Potential biases in the review process
We limited inclusion to studies that specified that their participants
were in palliative care or at an advanced stage of a disease. This
is likely to have led to a loss of data, as studies we excluded may
have included people with advanced disease but the authors did
not provide details on disease stage.
Agreements and disagreements with other
studies or reviews
There is one larger Cochrane review on laxatives, which is within
the general adult population (Lee-Robichaud 2010). It sought to
determine whether lactulose or polyethylene glycol is more effec-
tive at treating chronic constipation and faecal impaction. The
authors were able to combine the findings of some of the 10 eligi-
ble trials in various meta-analyses. They found that polyethylene
glycol was better than lactulose in outcomes of stool frequency
and form, and the need for rescue laxatives.
No trials of polyethylene glycol were identified in people receiving
palliative care. The findings from reviews in non-palliative care
populations are informative. However, it is important to evaluate
laxatives in palliative care populations because of the differences
inherent in this group that will impact, in a likely negative way, on
the effect of a laxative. In particular, people receiving palliative care
may differ from other populations in regards to the multifactorial
pathophysiology of constipation, the rapid course of their illness,
the presence of multiple organ failure, increased frailty, reduced
food intake and higher rates of polypharmacy. People receiving
palliative care may also have a higher risk of adverse effects (Bader
2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this second update, the conclusions on the effectiveness of lax-
atives remain unchanged.
The review cannot provide any information on what may be the
optimal laxative management for constipation in people receiv-
ing palliative care. The randomised controlled trials included in
this review did not show any differences in effectiveness of three
commonly used laxatives; senna, docusate and lactulose. However,
these studies are subject to bias and low power. None of the studies
evaluated the effectiveness of polyethylene glycol in this popula-
tion.
Implications for research
Rigorous and independent randomised controlled trialsmeasuring
standardised and clinically relevant outcomes in a clearly defined
population are needed to establish the effectiveness of laxatives
in the management of constipation in people receiving palliative
care. To help distinguish between different laxatives there is a need
to include measures on tolerability, quality of life, participant pref-
erence and costs.
High attrition rates in the included studies and the relatively small
numbers of eligible participants in any one palliative care unit
suggest that any trial of laxative efficacy should be multicentred.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agra 1998
Methods RCT, single-centre, parallel-group design
Participants 91 randomised male (n = 58) and female (n = 33) outpatients from a Spanish palliative
care unit. Of these, 75 remaining in the study for at least 7 days were analysed. All had
a documented cancer with a life expectancy of < 6 months. The most common cancer
was lung tumour (30%) followed by breast (11%)
Exclusion criteria: colectomy, steatorrhoea or aphagia; Karnofsky Index < 10% and
people having taken opioids or laxatives during the 72-hour period before the initiation
of the study
Baseline characteristics: mean age 69.8 years (SD 12.2) in senna group, 66.1 years (SD
11.0) in lactulose group; pain score 4.2 (SD 2.8) in senna group, 4.9 (SD 2.5) in lactulose
group; mean morphine doses 70.9 mg (SD 64.9) in senna group, 78.9 mg (SD 52.5) in
lactulose group
Interventions Oral liquid
Drug 1: lactulose starting 15 mL (10 g) twice daily
Drug 2: senna starting 0.4 mL (12 mg) twice daily
Daily doses were increased if no bowel movement for 3 days. Maximum doses senna 1.6
mL (48 mg), lactulose 60 mL (40 g). Drugs were given as a prophylactic when opioids
were started
Duration of treatment: 27 days
Outcomes Main outcome were defecation-free intervals of 72 hours, days with defecation, general
health status and treatment cost
Notes Trial authors recommended use of senna based on cost advantage
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...Randomisation stratified by age and gen-
der”; no other details
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The laxatives were supplied by the hospi-
tal pharmaceutical service and administered
by the Palliative Care Unit in uni-doses of
identical volume (the laxative was dissolved
in water), in closed opaque flasks to prevent
prescribers from identifying them. Yet, as
texture and taste could not be homogenized,
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Agra 1998 (Continued)
patients were able to differentiate between
one and the other drug”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 82% of recruited participants included in
analysis
16 lost to follow-up (6 in senna group, 10
in lactulose group) in first 4 days; 1 due to
diarrhoea and no response to treatment, 4
because of non-compliance, 4 due to death,
5 due to permanent hospitalisation and 2 to
relocation
By the end of the 27 days, 37 participants
were lost; 21 in senna group and 16 in lactu-
lose group. 3 developed vomiting, 5 refused
to continue in the protocol, 17 died and 12
were hospitalised
The authors stated that participants who
dropped out were not particularly different
from those who completed follow-up
Selective reporting (reporting bias) Unclear risk No details provided
Ramesh 1998
Methods RCT, single-centre, parallel-group design
Participants 36 male (n = 11) and female (n = 25) participants with advanced cancer in an Indian
palliative care unit aged ≥ 15 years who were started on oral morphine for the first time
and had opioid-induced constipation
Exclusion criteria: were infants and children aged < 15 years, people with intestinal
obstruction, people already taking laxatives, people who were constipated even before
the intake of morphine, people already undergoing Ayurvedic therapy as somemedicines
may have a laxative action
Most common cancers were lung, tongue, breast, oesophagus or cervix. Majority of the
participants were aged 51-70 years
Interventions Oral tablet
Drug 1: misrakasneham (an Ayurvedic preparation; starting at 2.5 mL)
Drug 2: senna (starting at 24 mg) in 3 steps of doses if previous level failed
Maximum doses: senna 72 mg, misrakasneham 10 mL
Duration of treatment: 2 weeks
Given as a prophylactic when opioids started
Outcomes Bowel movement
Notes Trial authors recommended use of misrakasneham based on favourable toxicity profile
and cost advantage. This preparation may be difficult to obtain for use in the UK
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Ramesh 1998 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated to the 2 study groups
(25 each) by drawing lots (sampling with
replacement)
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
High risk The difference between the physical forms
of the 2 drugs necessitated an open trial
rather than a double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20 (80%) participants in misrakasneham
group and 16 (64%) participants in senna
group completed the trial. 1 participant
from misrakasneham group and 4 partic-
ipants from senna group dropped out be-
cause of irregular laxative administration. 0
dropped out because of inefficacy
Unclear if used intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk No details provided
Sykes 1991a
Methods RCT, single-centre, cross-over group design
Participants 51 people with cancer in UK hospice who had not under gone bowel diversion, were
not clinically obstructed and who required a laxative. Participants were receiving either
> 80 or < 80 mg of strong opioid a day
Interventions Drug 1: senna plus lactulose (in equal quantities) liquid
Drug 2: equivalent volume of co-danthramer plus poloxamer
Starting doses of laxatives were set by the protocol in relation to opioid dosage and
subsequently modulated according to clinical response. No further details on doses
Duration of treatment: 1 week twice daily
Cross-over: switched to the alternative for 1 further week
Outcomes Stool form and frequency, failure (absence of a single stool passed spontaneously during
1 treatment week), use of rescue laxatives, participant’s assessment of bowel function,
participant preference and adverse events
Notes No details provided
Risk of bias
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Sykes 1991a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
High risk “Not possible because of physical charac-
teristics of drugs”
Incomplete outcome data (attrition bias)
All outcomes
High risk 58/117 participants completed the cross-
over (of the 58, 6 participants were ex-
cluded from analysis because of breaches in
the protocol and 1 as “data unclear”)
0 dropped out because of inefficacy
Not reported if intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk No details provided
Sykes 1991b
Methods RCT, single-centre, cross-over group design
Participants 118 inpatients with cancer in UK hospice who had had no bowel diversion, showed no
evidence of intestinal obstruction, required a laxative and had a life expectancy of at least
2 weeks
Interventions Drug 1: magnesium hydroxide plus liquid paraffin. Doses were modified according to
response. Mean dose 45 mL daily (week 1) and 49 mL daily (week 2)
Drug 2: senna plus lactulose. Doses were modified according to response. Mean dose 38
mL daily (week 1) and 34 mL daily (week 2)
Duration of each treatment: 1 week and then switched to the alternative for 1 week
Outcomes Stool frequency, rates of failure, diarrhoea, use of rescue laxatives and participant’s as-
sessments of bowel function
Notes Unpublished data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
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Sykes 1991b (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk “...blindingnot possible because of physical
characteristics of the drugs”
Incomplete outcome data (attrition bias)
All outcomes
High risk 42/118 participants completed cross-over
trial. 0 dropped out because of inefficacy
1 withdrew because of abdominal pain as-
sociated with the use of senna plus lactulose
Not reported if intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk No details provided
Tarumi 2013
Methods RCT, multicentre, parallel-group design
Participants 41 men and 23 women from three Canadian hospice units (95% had a cancer). Aged
38-90 years, mean age: 75.3 years in docusate plus senna group and 71.9 years in placebo
plus senna group
Exclusion criteria: people with a gastrointestinal stoma, people with a contraindication
to docusate, people prescribed docusate “as needed,” if prescribed in liquid or crushed
form, or if docusate was discontinued or withheld before the person was screened
Interventions Drug 1: docusate 100 mg twice daily plus sennosides (1-3 x 8.6 mg tablets taken 1-3
times daily)
Drug 2: placebo twice daily plus sennosides (1-3 x 8.6 mg tablets taken 1-3 times daily)
Duration of treatment: 10 days
Outcomes Primary outcomes: stool frequency, volume and consistency; secondary outcome: par-
ticipant perceptions of bowel movements
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code
Allocation concealment (selection bias) Low risk Allocation conducted independently by a
pharmacist who worked remote from study
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, proxies, attending physicians,
nursing staff and the research assistant col-
lecting the study data were blinded to the
study treatment
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Tarumi 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 56/74 (75%) participants completed the
study, 25 in docusate plus senna group, 31 in
placebo plus senna group. Reason for attri-
tion in docusate plus senna group included
2 unable to swallow the medicine, 3 discon-
tinued taking all oral medications, 1 moved,
2 died unrelated to docusate and 2 were re-
moved (reason not given). Reasons in the
placebo plus senna group include 5 unable
to swallow the medicine, 1 because of med-
ication administration error and 2 were re-
moved (reasons not given)
Selective reporting (reporting bias) Unclear risk No details provided
SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abernethy 2003 Did not assess the effects of laxatives in palliative care
Chen 2014 Did not assess the effects of laxatives in palliative care
Crowther 1978 Not a controlled trial
Daeninck 1999 Did not assess the effects of laxatives in palliative care
Foss 2001 Did not assess the effects of laxatives in palliative care
Foss 2009 Commentary on findings of an included randomised controlled trial
Haazen 1999 Did not assess the effects of laxatives in palliative care
Koninger 2004 Did not assess the effects of laxatives in palliative care
Maywin 2002 Did not assess the effects of laxatives in palliative care
Meissner 2009 Did not assess the effects of laxatives in palliative care
Moss 2008 Commentary on included randomised controlled trial
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(Continued)
Muir 2004 Did not assess the effects of laxatives in palliative care
Nadstawek 2008 Did not assess the effects of laxatives in palliative care
RCN 2006 Did not assess the effects of laxatives in palliative care
Saunders 2004 Did not assess the effects of laxatives in palliative care
Schoorl 1997 Mixed laxatives used. Not possible to distinguish effect of individual regimens
Spiller 2003 Did not assess the effects of laxatives in palliative care
Sykes 1996 Did not assess the effects of laxatives in palliative care
Sykes 1998 Not an effectiveness trial
Walsh 2000 Did not assess the effects of laxatives in palliative care
Wenk 2000 Not a randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT01189409 2014
Trial name or title Polyethylene Glycol versus Sennosides Study in Opioid-Induced Constipation in Cancer
Methods Randomised controlled trial
Participants People with cancer with constipation (unclear stage of cancer)
Interventions Polyethylene glycol versus sennosides
Outcomes 2010
Starting date Laxation
Contact information British Columbia Cancer Agency sponsor
Notes Estimated completed date 2015/2016
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NCT01416909 2014
Trial name or title Effectiveness of a Constipation Treatment Protocol (including different unnamed laxatives and doses)
Methods Randomised controlled trial
Participants People with cancer receiving opioids (unclear stage of cancer)
Interventions Constipation treatment protocol (including different unnamed laxatives and doses)
Outcomes Laxation
Starting date 2008
Contact information H. Lee Moffitt Cancer Center, Florida, US
Notes Documented estimated study completion date 2015
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Co-danthramer plus poloxamer versus senna plus lactulose
Outcome or subgroup Participants Effect estimate*
Bowel movements in participants receiving
strong opioid analgesia (taking ≥ 80 mg)
17 “Lactulose plus senna was associated with significantly higher frequency
(regardless of which laxative taken first) (P value = < 0.01)”
Bowel movements in participants receiving
opioid analgesia (< 80 mg) or no opioid
analgesia
21 “No statistical difference between the trial arms”
No bowel movement in treatment week Unclear While participants were receiving co-danthramer plus poloxamer, this
occurred 11 times versus once in senna plus lactulose group (P value =
0.01)
Suspension of laxative therapy for 24 hours Unclear Occurred more frequently with lactulose plus senna (15 cases) than co-
danthramer plus poloxamer (5 cases) (P value = 0.05)
Rescue laxatives Unclear 14participants received a rescue laxative onlywhile taking co-danthramer
plus poloxamer but not with senna plus lactulose. 4 participants received
rescue laxatives while taking senna plus lactulose but not with co-dan-
thramer plus poloxamer. 5 participants received rescue laxatives both
while taking both trial treatments
Participant assessment of bowel function Unclear The reportedmean change in participant assessment of their bowel func-
tion was not significant between drugs at the first week prior to cross-
over or in the week following cross-over
Participant preference 58 “While favourable comments about agents effectiveness and flavour were
evenly shared, twice as many patients disliked the flavour of co-dan-
thramer as that of lactulose with senna”
Diarrhoea Unclear “...diarrhoea resulted in the suspension of laxative therapy occurredmore
frequently with lactulose and senna compared to co-danthramer (15
versus 5)”
Adverse effects Unclear 2 participants reported per-anal soreness and burning on co-danthramer
plus poloxamer
Overall finding - Outcomes were mixed on laxation response
* If data available and appropriate effect estimate was presented as an odds ratio (OR) or a mean difference (MD) with 95% confidence
interval (CI). If not available or appropriate then effect was reported as stated in the trial.
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Table 2. Magnesium hydroxide plus liquid paraffin versus senna plus lactulose
Magnesium hydroxide plus liquid Participants Effect outcome*
Laxation response 35 “For all patients and for the subgroups who either were or were not
receiving strong opioids there was no statistical difference in stool fre-
quency between the two trial treatment groups”. At the end of the trial,
19/35 (54%) participants had bowel function they accepted as normal
Treatment failure 29 2 participants passed no spontaneous stool with either treatment
Loose stools unclear There was no significant difference between treatments in the proportion
of participants reporting loose stools
Rescue laxatives unclear “...rectal measures were used on ten occasions during treatment with
senna plus lactulose and 23 occasions while magnesium hydroxide plus
liquid paraffin was being used”
Participant assessment of constipation 35 OR 1.10; 95% CI 0.28 to 4.26**
Participant assessment of diarrhoea 35 OR 0.67; 95% CI 0.10 to 4.58**
Participant assessment of normality of
bowel function
35 OR 1.11; 95% CI 0.29 to 4.21**
Participant preference 32 8/32 (magnesium hydroxide plus liquid paraffin) versus 19/32 (senna
and lactulose group)
Adverse events Unclear In both groups, 1 participant found the treatment intolerably nauseating.
1 participant had gripping abdominal pain with lactulose and senna
Overall finding - No difference in laxation response
* If data available and appropriate effect estimate was presented as an odds ratio (OR) or a mean difference (MD) with 95% confidence
interval (CI). If not available or appropriate then effect was reported as stated in the trial. **Effect outcome used data prior to cross-
over.
Table 3. Misrakasneham versus senna
Outcome or subgroup Participants Effect estimate*
Satisfactory bowel movements with no ad-
verse effects
28 OR 7.67; 95% CI 0.37 to 158.01
Overall finding - No difference in laxation response
* If data available and appropriate effect estimate was presented as an odds ratio (OR) or a mean difference (MD) with 95% confidence
interval (CI). If not available or appropriate then effect was reported as stated in the trial.
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Table 4. Senna versus lactulose
Outcome or subgroup Participants Effect estimate*
Mean number of defecation days 75 MD -0.10; 95% CI -0.60 to 0.40
Defecation-free days 75 MD 0.00; 95% CI -0.48 to 0.48
General state of health 75 MD -0.10; 95% CI -0.31 to 0.11
Overall finding - No difference in laxation response
* If data available and appropriate effect estimate was presented as an odds ratio (OR) or a mean difference (MD) with 95% confidence
interval (CI). If not available or appropriate then effect was reported as stated in the trial.
Table 5. Docusate plus senna versus placebo plus senna
Outcome or subgroup Participants Effect estimate*
Stool frequency 56 No statistically significant difference in the overallmeannumber of bowel
movements per day between the docusate plus senna (x statistic = 0.74
(SD 0.47) and placebo plus senna groups (x statistic = 0.69, SD 0.37)
(P value = 0.58)
Bowel movement on ≥ 50% of days 56 OR 0.52; 95% CI 0.17 to 1.57
Stool volume 56 Trialists reported no significant difference between trial arms in stool
volume (P value = 0.06)
Stool consistency 56 Using the Bristol Stool Form Scale, more participants in the placebo plus
senna group had Type 4 (smooth and soft) and Type 5 (soft blobs). In
the docusate plus senna group, more participants had Type 3 (sausage,
cracks in surface) and Type 6 (mushy stool) (P value = 0.01)
Participants’ perceptions of the difficulty
and completeness of defecation
56 Nodifferences in reported difficulty in evacuation (13/40 in the docusate
group versus 14/56 in the placebo group; OR 1.44; 95% CI 0.59 to 3.
54). No difference in sense of completeness of evacuation (25/34 in the
docustate plus senna group versus 44/56 in the placebo plus senna group
; OR 0.76; 95% CI 0.28 to 2.05)
Overall finding - No difference in laxation response
* If data available and appropriate effect estimate is presented as an odds ratio (OR) or a mean difference (MD). If not available or
appropriate then effect is reported as stated in the trial. SD: standard deviation.
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A P P E N D I C E S
Appendix 1. Search strategies for 2014 update
Laxatives for the management of constipation in people receiving palliative care
Database Date searched Number of results
CENTRAL Issue 8 of 12, 2014 (The
Cochrane Library)
(searched 2010 to 2014)
10 September 2014 47
MEDLINE and MEDLINE in Process
(OVID)August 2010 to 9 September 2014
10 September 2014 147
EMBASE (OVID) August 2010 to 9
September 2014
10 September 2014 429
CINAHL (EBSCO) August 2010 to
September 2014
16 September 2014 40
Web of Science (SCI & CPCI-S) 2010 to
September 2014
16 September 2014 263
Total 926
After de-duplication 717
CENTRAL
#1 MeSH descriptor: [Constipation] this term only
#2 MeSH descriptor: [Defecation] this term only
#3 MeSH descriptor: [Fecal Incontinence] this term only
#4 MeSH descriptor: [Feces] this term only
#5 MeSH descriptor: [Diarrhea] this term only
#6 MeSH descriptor: [Irritable Bowel Syndrome] this term only
#7 (constipat* or (hard near/3 stool*) or (bowel near/3 symptom*) or (impact* near/3 stool*) or (impact* near/3 feces) or (impact*
near/3 faeces) or (fecal* near/3 incontin*) or (faecal* near/3 incontin*) or (fecal* near/3 impact*) or (faecal* near/3 impact*) or (loose
near/3 stool*) or diarrh* or feces or faeces):ti,ab,kw (Word variations have been searched)
#8 (defecat* or (bowel* near/3 function*) or (bowel* near/3 habit*) or (bowel* near/3 symptom*) or (evacuat* near/3 f?eces) or (evacuat*
near/3 bowel*) or (bowel* near/3 symptom*) or (bowel near/3 movement*) or (intestin* near/3 motility) or (colon near/3 transit*) or
(void* near/3 bowel*) or (strain* near/3 bowel*) or (irritable bowel syndrome)):ti,ab,kw (Word variations have been searched)
#9 MeSH descriptor: [Fecal Impaction] this term only
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 (cathartic* or laxative* or purgative* or stimulant or osmotic or supposit* or “faecal softener*” or bulk-forming or enema*):ti,ab,kw
(Word variations have been searched)
#12 MeSH descriptor: [Cathartics] explode all trees
#13 MeSH descriptor: [Laxatives] explode all trees
#14 (5-HT4 agonist or 5-hydroxytryptamine receptor subtype 4 agonist or actilax or actonorm* or aka hemp seed pill or aloe* or aludrox*
or anthraquinone* or apo-lactulose or (arachis near/2 oil) or aloin phenolphthalein or bethanechol or bifidobacterium supplement* or
bisacodyl* or (bowel near/2 cleaning near/2 solution*) or bran or trifyba or (dietary near/2 (fibre or fiber)) or “bowl cleansing” or (bulk
near/2 forming) or buckthrin):ti,ab,kw (Word variations have been searched)
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#15 (calcium polycarbophil or calsalettes* or califig* or capsuvac* or carbalax or carbellon* or cascara or castranol or casanthranol or
cellulose or celevac* or (chloride near/2 clinical near/2 activators) or cephulac or cholac or cilac or citroma or constilac or chronulac or
citramag* or citrafleet or codalax or codanthramer* or co-danthrusate* or codanthrusate or cologel* or colyte or creon* or colocynth or
danlax or dantron* or danthron* or dioctyl* or (dioctyl near/2 sodium near/2 sulphosuccinate) or didaccharide or docusate or dulcolax*
or duphalac* or dulcolax or docusol* or docisate sodium):ti,ab,kw (Word variations have been searched)
#16 (enulose or (epsom near/2 salt*) or ex-lax* or exlax or (f?ecal near/2 softener*) or fam-lax-senna* or emollients or fibrelief or fleet
enema or fleet phospho-soda or (fleet* near/2 fletcher*) or (fletcher* near/2 enemette*) or fortans or forlax or frangula or (fruit near/2
juice*) or fybogel* or frangula or generiac or glycerol or glycerin or glucitol or goitely or grangula* or golytely or ground-nut or ground
nut or heptalac or idrolax* or indoles or ispaghula or ispaghula or isogel* or ispagel* or (jackson* near/2 herb*) or jalap or (juno near/
2 junipah near/2 salts*) or kiwi or (klean near/2 prep*) or konsyl* or kristalose or lactuga* or lactitol or lactulose* or lactobacillus or
laxoberal* or laxido or (liquid near/2 paraffin) or Lubiprostone or linaclotide):ti,ab,kw (Word variations have been searched)
#17 (maalox* or macrogol* or magnesium hydroxide or (magnesium near/2 (salt* or compound* or hydroxide or sulphate* or citrate*))
or manevac or macrogol or magnesium sulphate or movicol* or (magnesium hydroxide) or manevac* or methylcellulose or (milk near/2
magnesia*) or mineral oil or (micolette near/2 micro-enema*) or (micralax near/2 micro-enema*) or miralax or moviprep or mucaine*
or mucogel* or movicol or neostigmine or (nylax near/2 senna*) or normax* or normacol* or norgine* or norgalax* or nutrizym* or
nutiteky or osmolax* or osmotic or osmoprep or operles*):ti,ab,kw (Word variations have been searched)
#18 (pancrease* or pancrex* or pancreatin* or pear or peanut oil or phenols or phenolphthalein* or phosphate* or (phosphate near/
2 enema*) or picolax* or PEG or (polyethylene near/2 glycol*) or PMF-100 or poloxalkol or poloxamer or (potter* near/2 cleansing
near/2 herb*) or prune* or Probiotic* or pricalopride or psyllium or pyridostigmine or regulose* or regulan* or (relaxit near/2 micro-
enema*) or receptors or roughage or rhubarb or rhuaka* or sanochemia or senna* or senokot* or senako* or serotonin agonists or
((sodium picosulfate or sodium) near/2 picosulfate) or sorbitol or sterculia* or suppositor* or (syrup near/3 fig*) or (sodium near/2
alginate) or (sodium near/2 acid near/2 phosphate) or (sodium near/2 (salts or citrate)) or stool softener* or sterculia or tegaserod or
transipeg or trilyte or visicol or yun-chang):ti,ab,kw (Word variations have been searched)
#19 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 MeSH descriptor: [Palliative Care] this term only
#21 MeSH descriptor: [Terminal Care] this term only
#22 MeSH descriptor: [Terminally Ill] this term only
#23 MeSH descriptor: [Hospice Care] this term only
#24 (palliat* or terminal* or endstage or hospice* or (end near/3 life) or (care near/3 dying) or ((advanced or late or last or end or final)
near/3 (stage* or phase*))):ti,ab,kw (Word variations have been searched)
#25 #20 or #21 or #22 or #23 or #24
#26 #25 and #19 and #10 Publication Year from 2010 to 2014
MEDLINE & MEDLINE in Process
1. Constipation/
2. Defecation/
3. Fecal Incontinence/
4. Feces/
5. Diarrhea/
6. Irritable Bowel Syndrome/
7. (constipat* or (hard adj3 stool*) or (bowel adj3 symptom*) or (impact* adj3 stool*) or (impact* adj3 feces) or (impact* adj3 faeces)
or (fecal* adj3 incontin*) or (faecal* adj3 incontin*) or (fecal* adj3 impact*) or (faecal* adj3 impact*) or (loose adj3 stool*) or diarrh*
or feces or faeces).tw.
8. (defecat* or (bowel* adj3 function*) or (bowel* adj3 habit*) or (bowel* adj3 symptom*) or (evacuat* adj3 f#eces) or (evacuat* adj3
f#eces) or (evacuat* adj3 bowel*) or (bowel* adj3 symptom*) or (bowel adj3 movement*) or (intestin* adj3 motility) or (colon adj3
transit*) or (void* adj3 bowel*) or (strain* adj3 bowel*) or (irritable adj bowel adj syndrome)).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier]
9. Fecal Impaction/
10. or/1-9
11. (cathartic* or laxative* or purgative* or stimulant or osmotic or supposit* or “faecal softener*” or bulk-forming or enema*).tw.
12. exp cathartics/ or exp laxatives/
13. (5-HT4 agonist or 5-hydroxytryptamine receptor subtype 4 agonist or actilax or actonorm* or aka hemp seed pill or aloe* or aludrox*
or anthraquinone* or apo-lactulose or (arachis adj2 oil) or aloin phenolphthalein or bethanechol or bifidobacterium supplement* or
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bisacodyl* or (bowel adj2 cleaning adj2 solution*) or bran or trifyba or (dietary adj2 (fibre or fiber)) or “bowl cleansing” or (bulk adj2
forming) or buckthrin).tw.
14. (calcium polycarbophil or calsalettes* or califig* or capsuvac* or carbalax or carbellon* or cascara or castranol or casanthranol or
cellulose or celevac* or (chloride adj2 clinical adj2 activators) or cephulac or cholac or cilac or citroma or constilac or chronulac or
citramag* or citrafleet or codalax or codanthramer* or co-danthrusate* or codanthrusate or cologel* or colyte or creon* or colocynth
or danlax or dantron* or danthron* or dioctyl* or (dioctyl adj2 sodium adj2 sulphosuccinate) or didaccharide or docusate or dulcolax*
or duphalac* or dulcolax or docusol* or docisate sodium).tw.
15. (enulose or (epsom adj2 salt*) or ex-lax* or exlax or (f#ecal adj2 softener*) or fam-lax-senna* or emollients or fibrelief or fleet enema
or fleet phospho-soda or (fleet* adj2 fletcher*) or (fletcher* adj2 enemette*) or fortans or forlax or frangula or (fruit adj2 juice*) or
fybogel* or frangula or generiac or glycerol or glycerin or glucitol or goitely or grangula* or golytely or ground-nut or ground nut or
heptalac or idrolax* or indoles or ispaghula or ispaghula or isogel* or ispagel* or (jackson* adj2 herb*) or jalap or (juno adj2 junipah
adj2 salts*) or kiwi or (klean adj2 prep*) or konsyl* or kristalose or lactuga* or lactitol or lactulose* or lactobacillus or laxoberal* or
laxido or (liquid adj2 paraffin) or Lubiprostone or linaclotide).tw.
16. (maalox* or macrogol* or magnesium hydroxide or (magnesium adj2 (salt* or compound* or hydroxide or sulphate* or citrate*))
or manevac or macrogol or magnesium sulphate or movicol* or (magnesium adj hydroxide) or manevac* or methylcellulose or (milk
adj2 magnesia*) or mineral oil or (micolette adj2 micro-enema*) or (micralax adj2 micro-enema*) or miralax or moviprep or mucaine*
or mucogel* or movicol or neostigmine or (nylax adj2 senna*) or normax* or normacol* or norgine* or norgalax* or nutrizym* or
nutiteky or osmolax* or osmotic or osmoprep or operles*).tw.
17. (pancrease* or pancrex* or pancreatin* or pear or peanut oil or phenols or phenolphthalein* or phosphate* or (phosphate adj2
enema*) or picolax* or PEG or (polyethylene adj2 glycol*) or PMF-100 or poloxalkol or poloxamer or (potter* adj2 cleansing adj2
herb*) or prune* or Probiotic* or pricalopride or psyllium or pyridostigmine or regulose* or regulan* or (relaxit adj2 micro-enema*)
or receptors or roughage or rhubarb or rhuaka* or sanochemia or senna* or senokot* or senako* or serotonin agonists or ((sodium
picosulfate or sodium) adj2 picosulfate) or sorbitol or sterculia* or suppositor* or (syrup adj3 fig*) or (sodium adj2 alginate) or (sodium
adj2 acid adj2 phosphate) or (sodium adj2 (salts or citrate)) or stool softener* or sterculia or tegaserod or transipeg or trilyte or visicol
or yun-chang).tw.
18. or/11-17
19. Palliative Care/
20. Terminal Care/
21. Terminally Ill/
22. Hospice Care/
23. (palliat* or terminal* or endstage or hospice* or (end adj3 life) or (care adj3 dying) or ((advanced or late or last or end or final) adj3
(stage* or phase*))).tw.
24. or/19-23
25. 10 and 18 and 24
EMBASE
1. Constipation/
2. Defecation/
3. Feces Incontinence/
4. Feces/
5. Diarrhea/
6. Irritable Colon/
7. (constipat* or (hard adj3 stool*) or (bowel adj3 symptom*) or (impact* adj3 stool*) or (impact* adj3 feces) or (impact* adj3 faeces)
or (fecal* adj3 incontin*) or (faecal* adj3 incontin*) or (fecal* adj3 impact*) or (faecal* adj3 impact*) or (loose adj3 stool*) or diarrh*
or feces or faeces).tw.
8. (defecat* or (bowel* adj3 function*) or (bowel* adj3 habit*) or (bowel* adj3 symptom*) or (evacuat* adj3 f#eces) or (evacuat* adj3
f#eces) or (evacuat* adj3 bowel*) or (bowel* adj3 symptom*) or (bowel adj3 movement*) or (intestin* adj3 motility) or (colon adj3
transit*) or (void* adj3 bowel*) or (strain* adj3 bowel*) or (irritable adj bowel adj syndrome)).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
9. Feces Impaction/
10. or/1-9
11. (cathartic* or laxative* or purgative* or stimulant or osmotic or supposit* or “faecal softener*” or bulk-forming or enema*).tw.
12. exp laxative/
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13. (5-HT4 agonist or 5-hydroxytryptamine receptor subtype 4 agonist or actilax or actonorm* or aka hemp seed pill or aloe* or aludrox*
or anthraquinone* or apo-lactulose or (arachis adj2 oil) or aloin phenolphthalein or bethanechol or bifidobacterium supplement* or
bisacodyl* or (bowel adj2 cleaning adj2 solution*) or bran or trifyba or (dietary adj2 (fibre or fiber)) or “bowl cleansing” or (bulk adj2
forming) or buckthrin).tw.
14. (calcium polycarbophil or calsalettes* or califig* or capsuvac* or carbalax or carbellon* or cascara or castranol or casanthranol or
cellulose or celevac* or (chloride adj2 clinical adj2 activators) or cephulac or cholac or cilac or citroma or constilac or chronulac or
citramag* or citrafleet or codalax or codanthramer* or co-danthrusate* or codanthrusate or cologel* or colyte or creon* or colocynth
or danlax or dantron* or danthron* or dioctyl* or (dioctyl adj2 sodium adj2 sulphosuccinate) or didaccharide or docusate or dulcolax*
or duphalac* or dulcolax or docusol* or docisate sodium).tw.
15. (enulose or (epsom adj2 salt*) or ex-lax* or exlax or (f#ecal adj2 softener*) or fam-lax-senna* or emollients or fibrelief or fleet enema
or fleet phospho-soda or (fleet* adj2 fletcher*) or (fletcher* adj2 enemette*) or fortans or forlax or frangula or (fruit adj2 juice*) or
fybogel* or frangula or generiac or glycerol or glycerin or glucitol or goitely or grangula* or golytely or ground-nut or ground nut or
heptalac or idrolax* or indoles or ispaghula or ispaghula or isogel* or ispagel* or (jackson* adj2 herb*) or jalap or (juno adj2 junipah
adj2 salts*) or kiwi or (klean adj2 prep*) or konsyl* or kristalose or lactuga* or lactitol or lactulose* or lactobacillus or laxoberal* or
laxido or (liquid adj2 paraffin) or Lubiprostone or linaclotide).tw.
16. (maalox* or macrogol* or magnesium hydroxide or (magnesium adj2 (salt* or compound* or hydroxide or sulphate* or citrate*))
or manevac or macrogol or magnesium sulphate or movicol* or (magnesium adj hydroxide) or manevac* or methylcellulose or (milk
adj2 magnesia*) or mineral oil or (micolette adj2 micro-enema*) or (micralax adj2 micro-enema*) or miralax or moviprep or mucaine*
or mucogel* or movicol or neostigmine or (nylax adj2 senna*) or normax* or normacol* or norgine* or norgalax* or nutrizym* or
nutiteky or osmolax* or osmotic or osmoprep or operles*).tw.
17. (pancrease* or pancrex* or pancreatin* or pear or peanut oil or phenols or phenolphthalein* or phosphate* or (phosphate adj2
enema*) or picolax* or PEG or (polyethylene adj2 glycol*) or PMF-100 or poloxalkol or poloxamer or (potter* adj2 cleansing adj2
herb*) or prune* or Probiotic* or pricalopride or psyllium or pyridostigmine or regulose* or regulan* or (relaxit adj2 micro-enema*)
or receptors or roughage or rhubarb or rhuaka* or sanochemia or senna* or senokot* or senako* or serotonin agonists or ((sodium
picosulfate or sodium) adj2 picosulfate) or sorbitol or sterculia* or suppositor* or (syrup adj3 fig*) or (sodium adj2 alginate) or (sodium
adj2 acid adj2 phosphate) or (sodium adj2 (salts or citrate)) or stool softener* or sterculia or tegaserod or transipeg or trilyte or visicol
or yun-chang).tw.
18. or/11-17
19. Palliative Therapy/
20. Terminal Care/
21. Terminally Ill Patient/
22. Hospice Care/
23. (palliat* or terminal* or endstage or hospice* or (end adj3 life) or (care adj3 dying) or ((advanced or late or last or end or final) adj3
(stage* or phase*))).tw.
24. or/19-23
25. 10 and 18 and 24
CINAHL
S27 S25 AND S26
S26 EM 20100801-20140930
S25 (S10 AND S18 AND S24)
S24 S19 OR S20 OR S21 OR S22 OR S23
S23 (palliat* or terminal* or endstage or hospice* or (end near/3 life)
or (care near/3 dying) or ((advanced or late or last or end or final)
near/3 (stage* or phase*)))
S22 (MH “Hospice Care”)
S21 (MH “Terminally Ill Patients”)
S20 (MH “Terminal Care”)
S19 (MH “Palliative Care”)
S18 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17
S17 (pancrease* or pancrex* or pancreatin* or pear or peanut oil or
phenols or phenolphthalein* or phosphate* or (phosphate near/2 enema*)
or picolax* or PEG or (polyethylene near/2 glycol*) or PMF-100 or
poloxalkol or poloxamer or (potter* near/2 cleansing near/2 herb*) or
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prune* or Probiotic* or pricalopride or psyllium or pyridostigmine or
regulose* or regulan* or (relaxit near/2 micro-enema*) or receptors or
roughage or rhubarb or rhuaka* or sanochemia or senna* or senokot* or
senako* or serotonin agonists or ((sodium picosulfate or sodium) near/2
picosulfate) or sorbitol or sterculia* or suppositor* or (syrup near/3
fig*) or (sodium near/2 alginate) or (sodium near/2 acid near/2
phosphate) or (sodium near/2 (salts or citrate)) or stool softener* or
sterculia or tegaserod or transipeg or trilyte or visicol or
yun-chang)
S16 (maalox* or macrogol* or magnesium hydroxide or (magnesium near/2
(salt* or compound* or hydroxide or sulphate* or citrate*)) or manevac
or macrogol or magnesium sulphate or movicol* or (magnesium hydroxide)
or manevac* or methylcellulose or (milk near/2 magnesia*) or mineral oil
or (micolette near/2 micro-enema*) or (micralax near/2 micro-enema*) or
miralax or moviprep or mucaine* or mucogel* or movicol or neostigmine or
(nylax near/2 senna*) or normax* or normacol* or norgine* or norgalax*
or nutrizym* or nutiteky or osmolax* or osmotic or osmoprep or
operles*)
S15 (enulose or (epsom near/2 salt*) or ex-lax* or exlax or (f?ecal
near/2 softener*) or fam-lax-senna* or emollients or fibrelief or fleet
enema or fleet phospho-soda or (fleet* near/2 fletcher*) or (fletcher*
near/2 enemette*) or fortans or forlax or frangula or (fruit near/2
juice*) or fybogel* or frangula or generiac or glycerol or glycerin or
glucitol or goitely or grangula* or golytely or ground-nut or ground nut
or heptalac or idrolax* or indoles or ispaghula or ispaghula or isogel*
or ispagel* or (jackson* near/2 herb*) or jalap or (juno near/2 junipah
near/2 salts*) or kiwi or (klean near/2 prep*) or konsyl* or kristalose
or lactuga* or lactitol or lactulose* or lactobacillus or laxoberal* or
laxido or (liquid near/2 paraffin) or Lubiprostone or linaclotide)
S14 (calcium polycarbophil or calsalettes* or califig* or capsuvac* or
carbalax or carbellon* or cascara or castranol or casanthranol or
cellulose or celevac* or (chloride near/2 clinical near/2 activators) or
cephulac or cholac or cilac or citroma or constilac or chronulac or
citramag* or citrafleet or codalax or codanthramer* or co-danthrusate*
or codanthrusate or cologel* or colyte or creon* or colocynth or danlax
or dantron* or danthron* or dioctyl* or (dioctyl near/2 sodium near/2
sulphosuccinate) or didaccharide or docusate or dulcolax* or duphalac*
or dulcolax or docusol* or docisate sodium)
S13 (5-HT4 agonist or 5-hydroxytryptamine receptor subtype 4 agonist or
actilax or actonorm* or aka hemp seed pill or aloe* or aludrox* or
anthraquinone* or apo-lactulose or (arachis near/2 oil) or aloin
phenolphthalein or bethanechol or bifidobacterium supplement* or
bisacodyl* or (bowel near/2 cleaning near/2 solution*) or bran or
trifyba or (dietary near/2 (fibre or fiber)) or “bowl cleansing” or
(bulk near/2 forming) or buckthrin)
S12 (MH “Cathartics”)
S11 (cathartic* or laxative* or purgative* or stimulant or osmotic or
supposit* or “faecal softener*” or bulk-forming or enema*)
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S9 (MH “Feces, Impacted”)
S8 (defecat* or (bowel* near/3 function*) or (bowel* near/3 habit*) or
(bowel* near/3 symptom*) or (evacuat* near/3 f?eces) or (evacuat* near/3
bowel*) or (bowel* near/3 symptom*) or (bowel near/3 movement*) or
33Laxatives for the management of constipation in people receiving palliative care (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(intestin* near/3 motility) or (colon near/3 transit*) or (void* near/3
bowel*) or (strain* near/3 bowel*) or (irritable bowel syndrome))
S7 (constipat* or (hard near/3 stool*) or (bowel near/3 symptom*) or
(impact* near/3 stool*) or (impact* near/3 feces) or (impact* near/3
faeces) or (fecal* near/3 incontin*) or (faecal* near/3 incontin*) or
(fecal* near/3 impact*) or (faecal* near/3 impact*) or (loose near/3
stool*) or diarrh* or feces or faeces)
S6 (MH “Irritable Bowel Syndrome”)
S5 (MH “Diarrhea”)
S4 (MH “Feces”)
S3 (MH “Fecal Incontinence”)
S2 (MH “Defecation”)
S1 (MH “Constipation”)
Web of Science (SCI & CPCI-S)
# 12
#11 AND #10 AND #3
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 11
TOPIC: ((palliat* or terminal* or endstage or hospice* or (end near/3 life) or (care near/3 dying) or ((advanced or late or last or end
or final) near/3 (stage* or phase*))))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 10
#9 OR #8 OR #7 OR #6 OR #5 OR #4
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 9
TOPIC: ((pancrease* or pancrex* or pancreatin* or pear or peanut oil or phenols or phenolphthalein* or phosphate* or (phosphate near/
2 enema*) or picolax* or PEG or (polyethylene near/2 glycol*) or PMF-100 or poloxalkol or poloxamer or (potter* near/2 cleansing
near/2 herb*) or prune* or Probiotic* or pricalopride or psyllium or pyridostigmine or regulose* or regulan* or (relaxit near/2 micro-
enema*) or receptors or roughage or rhubarb or rhuaka* or sanochemia or senna* or senokot* or senako* or serotonin agonists or
((“sodium picosulfate” or sodium) near/2 picosulfate) or sorbitol or sterculia* or suppositor* or (syrup near/3 fig*) or (sodium near/2
alginate) or (sodium near/2 acid near/2 phosphate) or (sodium near/2 (salts or citrate)) or stool softener* or sterculia or tegaserod or
transipeg or trilyte or visicol or yun-chang))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 8
TOPIC: ((maalox* or macrogol* or magnesium hydroxide or (magnesium near/2 (salt* or compound* or hydroxide or sulphate* or
citrate*)) or manevac or macrogol or magnesium sulphate or movicol* or (magnesium hydroxide) or manevac* or methylcellulose or
(milk near/2 magnesia*) or mineral oil or (micolette near/2 micro-enema*) or (micralax near/2 micro-enema*) or miralax or moviprep
or mucaine* or mucogel* or movicol or neostigmine or (nylax near/2 senna*) or normax* or normacol* or norgine* or norgalax* or
nutrizym* or nutiteky or osmolax* or osmotic or osmoprep or operles*))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 7
TOPIC: ((enulose or (epsom near/2 salt*) or ex-lax* or exlax or (f?ecal near/2 softener*) or fam-lax-senna* or emollients or fibrelief or
fleet enema or fleet phospho-soda or (fleet* near/2 fletcher*) or (fletcher* near/2 enemette*) or fortans or forlax or frangula or (fruit
near/2 juice*) or fybogel* or frangula or generiac or glycerol or glycerin or glucitol or goitely or grangula* or golytely or ground-nut or
ground nut or heptalac or idrolax* or indoles or ispaghula or ispaghula or isogel* or ispagel* or (jackson* near/2 herb*) or jalap or (juno
near/2 junipah near/2 salts*) or kiwi or (klean near/2 prep*) or konsyl* or kristalose or lactuga* or lactitol or lactulose* or lactobacillus
or laxoberal* or laxido or (liquid near/2 paraffin) or Lubiprostone or linaclotide))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 6
TOPIC: ((calcium polycarbophil or calsalettes* or califig* or capsuvac* or carbalax or carbellon* or cascara or castranol or casanthranol
or cellulose or celevac* or (chloride near/2 clinical near/2 activators) or cephulac or cholac or cilac or citroma or constilac or chronulac
or citramag* or citrafleet or codalax or codanthramer* or co-danthrusate* or codanthrusate or cologel* or colyte or creon* or colocynth
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or danlax or dantron* or danthron* or dioctyl* or (dioctyl near/2 sodium near/2 sulphosuccinate) or didaccharide or docusate or
dulcolax* or duphalac* or dulcolax or docusol* or docisate sodium))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 5
TS=((5-HT4 agonist or “5-hydroxytryptamine receptor subtype 4 agonist” or actilax or actonorm* or “aka hemp seed pill” or aloe*
or aludrox* or anthraquinone* or apo-lactulose or (arachis near/2 oil) or “aloin phenolphthalein” or bethanechol or bifidobacterium
supplement* or bisacodyl* or (bowel near/2 cleaning near/2 solution*) or bran or trifyba or (dietary near/2 (fibre or fiber)) or “bowl
cleansing” or (bulk near/2 forming) or buckthrin))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 4
TOPIC: ((cathartic* or laxative* or purgative* or stimulant or osmotic or supposit* or “faecal softener*” or bulk-forming or enema*))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 3
#2 OR #1
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 2
TOPIC: ((defecat* or (bowel* near/3 function*) or (bowel* near/3 habit*) or (bowel* near/3 symptom*) or (evacuat* near/3 f?eces) or
(evacuat* near/3 bowel*) or (bowel* near/3 symptom*) or (bowel near/3 movement*) or (intestin* near/3 motility) or (colon near/3
transit*) or (void* near/3 bowel*) or (strain* near/3 bowel*) or (irritable bowel syndrome)))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
# 1
TOPIC: ((constipat* or (hard near/3 stool*) or (bowel near/3 symptom*) or (impact* near/3 stool*) or (impact* near/3 feces) or
(impact* near/3 faeces) or (fecal* near/3 incontin*) or (faecal* near/3 incontin*) or (fecal* near/3 impact*) or (faecal* near/3 impact*)
or (loose near/3 stool*) or diarrh* or feces or faeces))
Indexes=SCI-EXPANDED, CPCI-S, Timespan=2010-2014
WH A T ’ S N E W
Last assessed as up-to-date: 10 September 2014.
Date Event Description
21 November 2014 New citation required and conclusions have changed This update includes only trials of laxatives in pallia-
tive care. The previous version included both laxatives
and methylnaltrexone. Another review specifically on
mu-opioid antagonists for patients in palliative care
will include the trials on methylnaltrexone which were
included in the earlier version of this review. The con-
clusion on laxatives have not been changed, but we
recommend readers of the previous version to re-read
this update
21 November 2014 New search has been performed A new search for trials on laxatives was undertaken in
September 2014; one new trial was identified
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H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 4, 2006
Date Event Description
6 July 2011 Amended Amendment to contributors of Feedback submitted for
Issue 6, 2011
11 May 2011 Feedback has been incorporated Feedback was received and the author has responded.
Please see the Feedback section in the review for details
6 December 2010 New citation required and conclusions have changed The background and methods were updated, three
new studies were added to the review (Portenoy 2008;
Slatkin 2009; Thomas 2008), and the conclusions were
revised to include Methylnaltrexone. The review was
updated by a new set of authors
20 August 2010 New search has been performed Search updated to August 2010.
30 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
MG, SW and CM developed the original protocol.
In the 2015 review update, BC, PS, PL and LJ independently assessed eligibility of studies in new searches. Data extraction undertaken
by BC and checked by LJ. Statistical support provided by VV.
Updating of all review sections was drafted by BC and checked and critiqued by other members of the review update team (LJ, PL, PS
, AT and VV).
D E C L A R A T I O N S O F I N T E R E S T
BC has no relevant conflicts of interest to declare.
LJ has no relevant conflicts of interest to declare.
VV has no relevant conflicts of interest to declare.
AT has no relevant conflicts of interest to declare.
PS has no relevant conflicts of interest to declare.
PL has no relevant conflicts of interest to declare.
Janssen-Cilag has funded a Marie Curie Care survey of the management of constipation in palliative care. Part of the remit of this study
included a systematic review of the use of laxatives in the management of constipation for people receiving palliative care. Janssen-Cilag
do not manufacture or promote laxatives.
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S O U R C E S O F S U P P O R T
Internal sources
• Marie Curie Cancer Care, UK.
External sources
• Janssen-Cilag Ltd UK in original review (but not for the 2010 or 2015 review updates), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
A key difference between the earlier update and this 2015 update is that the review no longer includes trials on methylnaltrexone.
Other differences by section are:
• Background: re-ordered, references updated.
• Inclusion criteria: excludes opioid antagonists.
• Methods: now includes further details on analysis and current methods of risk of bias assessment.
• Results: includes analysis of one new study.
• Discussion: conclusions changed following findings from the new study.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Palliative Care; Analgesics, Opioid [adverse effects]; Anthraquinones [therapeutic use]; Cathartics [adverse effects; ∗therapeutic use];
Constipation [chemically induced; ∗drug therapy]; Lactulose [therapeutic use]; Magnesium Hydroxide [therapeutic use]; Naltrexone
[adverse effects; ∗analogs & derivatives; therapeutic use]; Paraffin [therapeutic use]; Quaternary Ammonium Compounds [adverse
effects; therapeutic use]; Randomized Controlled Trials as Topic; Senna Extract [therapeutic use]
MeSH check words
Humans
37Laxatives for the management of constipation in people receiving palliative care (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
